RELATING TO HUMAN SERVICES -- THE RHODE ISLAND PRESCRIPTION DRUG, PURCHASING POOL ACT
Impact
With the establishment of the Rhode Island Prescription Drug Purchasing Pool, the law is anticipated to significantly alter the landscape of prescription drug procurement within the state. By enabling joint purchases, this act could lead to substantial cost savings for local governmental bodies and private enterprises, as they leverage collective bargaining power to negotiate better prices. Additionally, the administration has the authority to regulate eligibility and establish rules for participation, ensuring that the program is efficiently managed and resources are utilized effectively. This framework aims to coordinate with other existing programs to further enhance the price reduction capabilities for state residents.
Summary
House Bill H8383, also known as the Rhode Island Prescription Drug Purchasing Pool Act, introduces a state-operated program designed to facilitate the purchasing of prescription drugs for various employers and health insurance providers. The bill aims to maximize the discounts that can be obtained by participants through collective purchasing. Specifically, it allows nonstate public employers, qualified private employers, and health insurance carriers to purchase prescription medication under the authority stipulated by the state, thereby potentially lowering costs associated with prescription drug expenses for these entities and their members.
Contention
Despite its potential benefits, H8383 may also generate discussions regarding the balance of power between state and local governance. Some opponents might question the implications of a statewide purchasing program on local control over health-related decision-making. Critics could argue that while the intention to reduce costs is commendable, it may unintentionally limit local entities' ability to choose their suppliers or negotiate on their terms. Moreover, the act does not create a risk pool, thereby maintaining the responsibility of each participating entity to cover the full costs, which has been a point of contention in legislative discussions regarding overall accountability and affordability.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Amends Rhode Island’s existing healthcare services funding plan act by adding an account relating to a new psychiatry resource network to fund Rhode Island’s present PediPRN and MomsPRN.
Amends Rhode Island’s existing healthcare services funding plan act by adding an account relating to a new psychiatry resource network to fund Rhode Island’s present PediPRN and MomsPRN.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
Adds to the powers and duties of the OHIC the undertaking of analyses, reports, studies, and recommendations with respect to reimbursement and financing for the provision of primary care services to Rhode Islanders.
Prohibits the Rhode Island medical assistance program and managed care organizations that it contracts with from requiring prior authorization or step therapy protocol for a prescription of a nonpreferred anticonvulsant or antipsychotic.
Establishes a state-run prescription drug purchasing pool, available for participation by nonstate public employers, private employers, and health insurance carriers, to maximize the value of drug discounts available to participants.
Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.